Fig. 1 · Structure

Documents & Downloads

JZL195

Cat. No. A12390 CAS 1210004-12-8

dual FAAH/MAGL inhibitor

JZL195 is a selective and efficacious dual FAAH/MAGL inhibitor with IC50 of 13 nM and 19 nM for mouse brain FAAH and MAGL respectively.

In Stock

Publications for JZL195

2 publications citing this product

  1. Lakhan S Khara, .et al. , J Exp Biol, 2022, May 1;225(9):jeb244146 PMID: 35438163
  2. Md Shah Sufian, .et al. , J Exp Biol, 2021, 21 JUNE PMID: 34435626

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

JZL195 inhibits FAAH and MAGL, with assay-dependent IC50 values: 13 and 19 nM in mouse-brain competitive activity-based profiling, and 2 and 4 nM in substrate-hydrolysis assays. It also inhibits ABHD6 at higher concentrations; selectivity depends on assay and target coverage. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

JZL195 Research Summary

This section summarizes 2 in vitro studies and 3 in vivo studies of JZL195 from 3 published references. In vitro models include Wistar rat epididymal white adipose tissue explants. In vivo models include male C57BL/6 mice.

JZL195 In Vitro Studies

In rat white-adipose explants, 10 µM JZL195 for 3 h increased 2-AG and reduced basal glycerol release. The AEA increase was not significant. These tissue results support model-specific endocannabinoid modulation. [2]

Assay-dependent FAAH/MAGL inhibition and selectivity

Biochemical assay · Mouse brain membranes and recombinant FAAH/MAGL expressed in COS7 cells; biochemical preparations [1]

JZL195 inhibited both hydrolases in substrate and competitive activity-based assays. ABHD6 inhibition at higher concentrations limits interpretation as an exclusively dual-target probe.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FAAH and MAGL inhibition in mouse brain membranesIC50 FAAH 13 nM; MAGL 19 nM[1]
AEA hydrolysis by FAAH and 2-AG hydrolysis by MAGLIC50 FAAH 2 nM; MAGL 4 nM[1]
Additional serine-hydrolase activitySelectivity ABHD6 inhibited at higher concentrations; NTE IC50 >5 µM with ≈50% maximal inhibition[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; IC50 values below are endpoints, not treatment concentrations.
Exposure duration
30 min preincubation at 37 °C
Method
Competitive FP-rhodamine ABPP and LC-MS substrate-hydrolysis assays; 1 µM FP-Rh or 100 µM AEA/2-AG added after preincubation.
Reported limits
Assay vehicle not specified in the read main-text locations; detailed SI not retrieved.
Methods and source locations

Compound reported in the paper: JZL195

Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.

Fig. 1A–E; Results, Development of JZL195; Materials and Methods, In Vitro studies with Inhibitors

FAAH and MAGL inhibition in mouse brain membranes: Competitive FP-Rh ABPP; values reported in Results, not estimated from gel. — Results, Development of JZL195; Fig. 1C

AEA hydrolysis by FAAH and 2-AG hydrolysis by MAGL: Substrate assays in recombinant-enzyme and brain membrane preparations; Fig. 1D/E show means ± SEM of three independent experiments. — Results, Development of JZL195; Fig. 1D–E

Additional serine-hydrolase activity: Competitive ABPP; restricted to detectable brain serine hydrolases. — Results, Development of JZL195; Fig. 1C

Rat adipose explants: lipid accumulation and basal lipolysis

Cell-based study · Wistar rat epididymal white adipose tissue explants [2]

JZL195 increased 2-AG and reduced basal glycerol release. AEA did not increase significantly in the same lipid assay. These are tissue-explant observations, not isolated-cell or human treatment data.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Explant 2-AG and AEA contentSignificance versus vehicle 2-AG increased, P<0.05; AEA P=0.1375 (not significant); n=6/group[2]
Basal glycerol productionDirection and significance Decreased versus vehicle, P<0.05; n=3 rats/group, explants treated in triplicate[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
3 h
Method
Ex-vivo rat WAT incubation; mass-spectrometric tissue lipid quantitation and colorimetric medium glycerol assay.
Vehicle
0.1% DMSO
Reported limits
Rat sex is not specified in the read Animals and Diets sentence. Paper does not supply independent lot characterization at selected locations.
Methods and source locations

Compound reported in the paper: JZL195

Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.

Fig. 1C–D and caption; first Results subsection; Methods, Drugs / Preparation and Treatment of Rodent and Human WAT Explants / Glycerol assays / Endocannabinoid quantitation

Explant 2-AG and AEA content: Fig. 1C lipid assay; means ± SEM; exact AEA P read from viewed image, no bar height estimated. — Fig. 1C and caption; first Results subsection

Basal glycerol production: Colorimetric glycerol assay; mean ± SEM. Technical triplicates are not counted as independent animals. — Fig. 1D and caption; Methods, Glycerol assays

JZL195 In Vivo Studies

In male C57BL/6 mice, a single intraperitoneal JZL195 dose series increased brain AEA and 2-AG at 4 h while reducing endocannabinoid-hydrolyzing activities. [1]

In a mouse CCI neuropathic-pain model, JZL195 reduced mechanical and cold allodynia, with open-field suppression at higher doses. Selected anti-allodynic responses persisted through five daily injections, but the higher dose also produced behavioral effects. The 3 mg/kg regimen did not significantly improve mechanical threshold. [3]

Brain target engagement and endocannabinoid elevation

Animal study · Male C57BL/6 mice [1]

A single JZL195 dose series reduced brain FAAH/MAGL/ABHD6 activities and AEA/2-AG hydrolysis, with increased brain AEA and 2-AG relative to vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Brain hydrolase activities and endocannabinoid levelsDose-dependent response 3–20 mg·kg−1; n=3–5 mice/group; means ± SEM[1]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Treatment course
Brain assessed 4 h later
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
JZL195 dose-response series
3, 8 and 20 mg·kg−1
Vehicle-treated miceReduced hydrolase activity; elevated brain AEA and 2-AG.[1]
JZL195 dose-response series
Model: Male C57BL/6 mice
Reported limits: Vehicle composition not retrieved from SI.
Methods and source locations

Compound reported in the paper: JZL195

Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.

Fig. 2A–D and caption; Results, JZL195 Inhibits Endocannabinoid Hydrolysis and Elevates 2-AG and AEA Levels in Vivo

Brain hydrolase activities and endocannabinoid levels: ABPP; substrate hydrolysis; brain lipid assays. Increased AEA/2-AG and reduced hydrolysis; no exact bar heights inferred. — Fig. 2A–D and caption; corresponding Results

JZL195 dose-response series · Fig. 2A–D and caption

Acute anti-allodynic dose response and behavioral limits

Animal study · C57BL/6 mice, day 7 after sciatic-nerve chronic constriction injury (CCI) [3]

JZL195 reduced mechanical and cold allodynia. Locomotor suppression occurred at higher doses, and motor/bar assays were complicated by hyper-reactivity at the highest doses.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical paw-withdrawal thresholdED50 2.1 (1.3–3.4) mg·kg−1[3]
Acetone-evoked responsesED50 1.5 (0.9–2.4) mg·kg−1[3]
Suppression of open-field crossingsED50 10.3 (7.2–14.7) mg·kg−1[3]
Hyper-reactivity affecting bar/rotarod interpretationObserved animals 1/6 at 18 mg·kg−1; 3/6 at 30 mg·kg−1[3]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Single injection
Treatment course
Day 7 post-CCI
Vehicle
2% randomly methylated β-cyclodextrin, 15% DMSO and 5% Tween-80 in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Acute JZL195 dose series
0.1–30 mg·kg−1
Matched vehicle; pre-drug values; CCI/sham model validation described in series 1Reduced allodynia; higher-dose locomotor and motor/bar effects.[3]
Acute JZL195 dose series
Model: C57BL/6 CCI mice; n=6/dose
Methods and source locations

Compound reported in the paper: JZL195

Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.

Methods, Drugs and administration / Experimental protocols series 3 / Analysis; Results, Effect of JZL195; Fig. 3; Table 1

Mechanical paw-withdrawal threshold: Sigmoidal dose-response fit; table reports mean (95% confidence interval); n=6/dose; figures mean ± SEM. — Table 1; Fig. 3A; Results, Effect of JZL195; Analysis

Acetone-evoked responses: Same dose-response design; mean (95% confidence interval), not SEM. — Table 1; Fig. 3A

Suppression of open-field crossings: Mean (95% confidence interval); open-field raw crossings at 2 h. — Table 1; Fig. 3C

Hyper-reactivity affecting bar/rotarod interpretation: Pop-corning prevented full sigmoidal dose responses; bar/rotarod ED50 not determined. — Results, Effect of JZL195; Table 1 footnote a; Fig. 3B

Acute JZL195 dose series · Methods, series 3; Fig. 3; Table 1

Five-day dosing preserves selected anti-allodynic responses

Animal study · C57BL/6 mice; treatment starts day 7 post-CCI [3]

Cold anti-allodynia persisted at 3 and 18 mg·kg−1 on treatment days 1 and 5. Mechanical threshold improved at 18 mg·kg−1, but not significantly at 3 mg·kg−1. Higher-dose cataleptic and locomotor effects limit interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mechanical and acetone responses on treatment days 1 and 5Within-day and between-day comparisons Mechanical: 3 mg·kg−1 P>0.05; 18 mg·kg−1 P<0.01 on day 1 and P<0.001 on day 5. Acetone: 3 mg·kg−1 P<0.01; 18 mg·kg−1 P<0.0001 on both days.[3]
Bar, rotarod and open-field responsesBehavioral limits 18 mg·kg−1 increased bar latency on days 1 and 5 (<5% MPE); day-5 open-field crossings lower than pre-CCI.[3]

Conditions shared by the study groups

Route
Subcutaneous
Frequency
Once daily
Treatment course
Five consecutive days beginning day 7 post-CCI
Vehicle
2% randomly methylated β-cyclodextrin, 15% DMSO and 5% Tween-80 in saline
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
JZL195 3 mg·kg−1Vehicle group and own pre-injection values; pre-CCI for open-field comparisonReduced acetone responses on days 1 and 5; mechanical change not significant.[3]
JZL195 18 mg·kg−1Vehicle group and own pre-injection values; pre-CCI for open-field comparisonReduced acetone responses and increased mechanical threshold on days 1 and 5; increased bar latency; lower day-5 open-field activity versus pre-CCI.[3]
JZL195 3 mg·kg−1
Model: C57BL/6 CCI mice; n=6/group
JZL195 18 mg·kg−1
Model: C57BL/6 CCI mice; n=6/group
Methods and source locations

Compound reported in the paper: JZL195

Applies to the reported JZL195 material and model; does not establish identity, potency or performance of an Adooq lot.

Methods, series 4; Results, Repeated administration of JZL195; Fig. 6A–E and caption

Mechanical and acetone responses on treatment days 1 and 5: Pre-/post-injection comparisons; post-injection day 5 versus day 1 not significant at either dose (P>0.05); n=6/group; mean ± SEM. — Results, Repeated administration; Fig. 6A–B

Bar, rotarod and open-field responses: No significant within-day rotarod effect at either dose. Post-injection crossings did not differ significantly between days 1 and 5. — Results, Repeated administration; Fig. 6C–E

JZL195 3 mg·kg−1 · Methods, series 4; Fig. 6 and corresponding Results

JZL195 18 mg·kg−1 · Methods, series 4; Fig. 6 and corresponding Results

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1210004-12-8
Applications dual FAAH/MAGL inhibitor
Formula C24H23N3O5
Molecular Weight 433.46
SMILES
O=C(N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1)OC(C=C4)=CC=C4[N+]([O-])=O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 42 mg/mL (96.89 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

JZL195 Research References

  1. [1] Jonathan Z Long, Daniel K Nomura, Robert E Vann, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo Proceedings of the National Academy of Sciences of the United States of America (2009). PMID: 19918051 DOI: 10.1073/pnas.0909411106 Source material
  2. [2] Chloé Buch, Tania Muller, Julia Leemput, et al. Endocannabinoids Produced by White Adipose Tissue Modulate Lipolysis in Lean but Not in Obese Rodent and Human Frontiers in Endocrinology (2021). PMID: 34434170 DOI: 10.3389/fendo.2021.716431 Source material
  3. [3] Nicholas S Adamson Barnes, Vanessa A Mitchell, Nicholas P Kazantzis, et al. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine neuropathic pain model British Journal of Pharmacology (2016). PMID: 26398331 DOI: 10.1111/bph.13337 Source material

Publications

2 publications citing this product

  1. Lakhan S Khara, .et al. , J Exp Biol, 2022, May 1;225(9):jeb244146 PMID: 35438163
  2. Md Shah Sufian, .et al. , J Exp Biol, 2021, 21 JUNE PMID: 34435626

Added to your cart

View Cart Checkout
Loading...